Chad Billingsley and the Dodgers are searching for answers

0 Comments

Chad Billingsley made his first All-Star team last season by going 9-4 with a 3.38 ERA in the first half, but then struggled so much in the second half that he was nearly left off the Dodgers’ postseason roster and has now allowed 14 runs in 14 innings this year.
Through mid-June of last season Billingsley was 44-22 with a 3.28 ERA in 530.1 career innings, and at just 24 years old looked like one of the most promising young starters in baseball. Since then he’s 4-8 with a 5.43 ERA in 117.2 innings, including back-to-back clunkers.
Joe Torre has made it clear that he’s sticking with Billingsley in the rotation, suggesting that a lack of confidence is to blame for his collapse. Billingsley disagrees:

That’s not an issue. I’ve been feeling good on the mound, as far as my delivery, my pitches. My arm feels good, my pitches feel good, my mechanics feel good. You have these times. I’m not going out there and walking guys. I’m going after guys. I’m making them beat me. I made some good pitches. I wasn’t walking guys.

As far as everything I wanted to work on between last start and this start, I thought I accomplished it. I mean … honestly, I don’t know. Last year, the second half, I felt like I was battling myself. I couldn’t repeat my delivery. Now, I feel like I’m repeating my delivery consistently. I’m throwing the ball in areas that I want to. I thought I was throwing quality pitches.

He’s obviously just searching for answers, but the problem for Billingsley is that if he’s right and confidence, mechanics, and command aren’t to blame then he’s either injured (which seemingly hasn’t even been hinted at) or simply no longer a good pitcher (which would be pretty unlikely at age 25). Every player goes through slumps, but 120 innings of 5.50 ERA pitching from a 25-year-old who began his career with 530 innings of 3.40 ERA pitching sure seems like something beyond that.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.